TABLE OF CONTENTS
1 INTRODUCTION 55
1.1 OBJECTIVES OF THE STUDY 55
1.2 MARKET DEFINITION 55
1.3 OVERVIEW OF THE NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET 55
1.4 CURRENCY AND PRICING 57
1.5 LIMITATIONS 57
1.6 MARKETS COVERED 58
2 MARKET SEGMENTATION 61
2.1 MARKETS COVERED 61
2.2 GEOGRAPHICAL SCOPE 62
2.3 YEARS CONSIDERED FOR THE STUDY 63
2.4 DBMR TRIPOD DATA VALIDATION MODEL 64
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 67
2.6 MULTIVARIATE MODELLING 68
2.7 MARKET APPLICATION COVERAGE GRID 69
2.8 TEST TYPE LIFELINE CURVE 70
2.9 DBMR MARKET POSITION GRID 71
2.10 VENDOR SHARE ANALYSIS 72
2.11 SECONDARY SOURCES 73
2.12 ASSUMPTIONS 73
3 EXECUTIVE SUMMARY 74
4 PREMIUM INSIGHTS 77
4.1 PESTLE ANALYSIS 78
4.2 PORTER ANALYSIS 79
4.3 EPIDEMIOLOGY 80
5 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, REGULATIONS 81
6 INDUSTRY INSIGHTS 85
7 MARKET OVERVIEW 87
7.1 DRIVERS 89
7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION 89
7.1.2 INCREASING EARLY DIAGNOSIS OF LIVER CANCER 90
7.1.3 INCREASING CASES OF LIVER CANCER 92
7.1.4 RISE IN DIAGNOSTIC PRODUCT APPROVALS 93
7.2 RESTRAINTS 95
7.2.1 BARRIERS TO LIVER CANCER DIAGNOSIS AND POOR PROGNOSIS 95
7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY OF LIVER CANCER DIAGNOSIS 96
7.3 OPPORTUNITIES 96
7.3.1 INCREASING AWARENESS TOWARDS LIVER CANCER 96
7.3.2 GOVERNMENT INITIATIVES TOWARD LIVER CANCER DIAGNOSTICS 96
7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 97
7.4 CHALLENGES 98
7.4.1 STRICT REGULATIONS FOR THE APPROVAL OF LIVER CANCER DIAGNOSTIC PRODUCTS 98
7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE 99
8 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 100
8.1 OVERVIEW 101
8.2 IMAGING TEST 104
8.2.1 MAGNETIC RESONANCE IMAGING (MRI) 105
8.2.1.1 MR ANGIOGRAPHY (MRA) 105
8.2.1.2 MR CHOLANGIOPANCREATOGRAPHY 106
8.2.2 COMPUTED TOMOGRAPHY 106
8.2.3 POSITRON EMISSION TOMOGRAPHY 106
8.2.4 ULTRASOUND 106
8.2.5 OTHERS 106
8.3 GENOMIC TEST 106
8.4 BIOPSY 107
8.4.1 FINE NEEDLE ASPIRATION BIOPSY 108
8.4.2 CORE NEEDLE BIOPSY 108
8.4.3 LAPAROSCOPY 108
8.5 OTHERS 109
9 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 110
9.1 OVERVIEW 111
9.2 STAGE III 114
9.3 STAGE II 115
9.4 STAGE IV 116
9.5 STAGE I 117
9.6 STAGE 0 118
10 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 119
10.1 OVERVIEW 120
10.2 SECONDARY LIVER CANCER 123
10.2.1 HEMANGIOMA 124
10.2.2 HEPATIC ADENOMA 124
10.2.3 FOCAL NODULAR HYPERPLASIA 124
10.3 PRIMARY LIVER CANCER 124
10.3.1 HEPATOCELLULAR CARCINOMA (HCC) 125
10.3.2 INTRAHEPATIC CHOLANGIOCARCINOMA (BILE DUCT CANCER) 125
10.3.3 ANGIOSARCOMA HEMANGIOSARCOMA 126
10.3.4 HEPATOBLASTOMA 126
11 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT 127
11.1 OVERVIEW 128
11.2 PLATFORM BASED PRODUCTS 131
11.2.1 NEXT GENERATION SEQUENCING 132
11.2.2 MICROARRAYS 132
11.2.3 PCR 132
11.2.4 OTHERS 132
11.3 INSTRUMENT BASED PRODUCTS 132
11.3.1 IMAGING 133
11.3.2 BIOPSY 133
11.4 KITS AND REAGENTS 134
11.4.1 ELISA TEST KITS 135
11.4.2 CASSETTE TEST KITS 135
11.4.3 OTHERS 135
11.5 OTHER CONSUMABLES 135
12 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION 136
12.1 OVERVIEW 137
12.2 SCREENING 140
12.2.1 PLATFORM BASED PRODUCTS 141
12.2.2 INSTRUMENT BASED PRODUCTS 141
12.2.3 KITS AND REAGENTS 141
12.2.4 OTHER CONSUMABLES 141
12.3 DIAGNOSTIC AND PREDICTIVE 141
12.3.1 PLATFORM BASED PRODUCTS 142
12.3.2 INSTRUMENT BASED PRODUCTS 142
12.3.3 KITS AND REAGENTS 142
12.3.4 OTHER CONSUMABLES 143
12.4 PROGNOSTIC 143
12.4.1 PLATFORM BASED PRODUCTS 144
12.4.2 INSTRUMENT BASED PRODUCTS 144
12.4.3 KITS AND REAGENTS 144
12.4.4 OTHER CONSUMABLES 144
12.5 RESEARCH 144
12.5.1 PLATFORM BASED PRODUCTS 146
12.5.2 INSTRUMENT BASED PRODUCTS 146
12.5.3 KITS AND REAGENTS 146
12.5.4 OTHER CONSUMABLES 146
13 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 147
13.1 OVERVIEW 148
13.2 FLUORESCENT IN SITU HYBRIDIZATION 151
13.3 NEXT GENERATION SEQUENCING 152
13.4 FLUORIMMUNOASSAY 153
13.5 COMPARATIVE GENOMIC HYBRIDIZATION 154
13.6 IMMUNOHISTOCHEMICAL 155
13.7 OTHERS 156
14 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER 157
14.1 OVERVIEW 158
14.2 MALE 161
14.3 FEMALE 162
15 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY END USER 163
15.1 OVERVIEW 164
15.2 HOSPITALS 167
15.3 DIAGNOSTIC CENTERS 168
15.4 CANCER RESEARCH CENTERS 169
15.5 AMBULATORY SURGICAL CENTERS 170
15.6 ACADEMIC INSTITUTES 171
15.7 OTHERS 172
16 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 173
16.1 OVERVIEW 174
16.2 DIRECT TENDER 177
16.3 RETAIL SALES 178
16.4 OTHERS 179
17 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY REGION 180
17.1 NORTH AMERICA 181
17.1.1 U.S. 194
17.1.2 CANADA 202
17.1.3 MEXICO 210
18 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 218
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 218
19 SWOT ANALYSIS 219
20 COMPANY PROFILE 220
20.1 F. HOFFMANN-LA ROCHE LTD. 220
20.1.1 COMPANY SNAPSHOT 220
20.1.2 REVENUE ANALYSIS 220
20.1.3 COMPANY SHARE ANALYSIS 221
20.1.4 PRODUCT PORTFOLIO 221
20.1.5 RECENT DEVELOPMENT 221
20.2 KONINLIJKE PHILIPS N.V. 222
20.2.1 COMPANY SNAPSHOT 222
20.2.2 REVENUE ANALYSIS 222
20.2.3 COMPANY SHARE ANALYSIS 223
20.2.4 PRODUCT PORTFOLIO 223
20.2.5 RECENT DEVELOPMENT 223
20.3 THERMO FISHER SCIENTIFIC INC. 224
20.3.1 COMPANY SNAPSHOT 224
20.3.2 REVENUE ANALYSIS 224
20.3.3 COMPANY SHARE ANALYSIS 225
20.3.4 PRODUCT PORTFOLIO 225
20.3.5 RECENT DEVELOPMENT 225
20.4 BD 226
20.4.1 COMPANY SNAPSHOT 226
20.4.2 REVENUE ANALYSIS 226
20.4.3 COMPANY SHARE ANALYSIS 227
20.4.4 PRODUCT PORTFOLIO 227
20.4.5 RECENT DEVELOPMENTS 228
20.5 SIEMENS HEALTHCARE GMBH 229
20.5.1 COMPANY SNAPSHOT 229
20.5.2 REVENUE ANALYSIS 229
20.5.3 COMPANY SHARE ANALYSIS 230
20.5.4 PRODUCT PORTFOLIO 230
20.5.5 RECENT DEVELOPMENT 230
20.6 AGILENT TECHNOLOGIES, INC. 231
20.6.1 COMPANY SNAPSHOT 231
20.6.2 REVENUE ANALYSIS 231
20.6.3 PRODUCT PORTFOLIO 232
20.6.4 RECENT DEVELOPMENTS 232
20.7 ABK BIOMEDICAL INC. 233
20.7.1 COMPANY SNAPSHOT 233
20.7.2 PRODUCT PORTFOLIO 233
20.7.3 RECENT DEVELOPMENT 233
20.8 AB SCIEX PTE LTD. (SUBSIDIARY OF DANAHER.) 234
20.8.1 COMPANY SNAPSHOT 234
20.8.2 REVENUE ANALYSIS 234
20.8.3 PRODUCT PORTFOLIO 235
20.8.4 RECENT DEVELOPMENT 235
20.9 ALTOGEN BIOSYSTEMS 236
20.9.1 COMPANY SNAPSHOT 236
20.9.2 PRODUCT PORTFOLIO 236
20.9.3 RECENT DEVELOPMENT 236
20.10 BIOCEPT, INC. 237
20.10.1 COMPANY SNAPSHOT 237
20.10.2 REVENUE ANALYSIS 237
20.10.3 PRODUCT PORTFOLIO 238
20.10.4 RECENT DEVELOPMENT 238
20.11 BODITECH MED INC. 239
20.11.1 COMPANY SNAPSHOT 239
20.11.2 PRODUCT PORTFOLIO 239
20.11.3 RECENT DEVELOPMENTS 239
20.12 DIAGNOSTIC BIOSYSTEMS INC. 240
20.12.1 COMPANY SNAPSHOT 240
20.12.2 PRODUCT PORTFOLIO 240
20.12.3 RECENT DEVELOPMENT 240
20.13 DIAZYME LABORATORIES, INC. 241
20.13.1 COMPANY SNAPSHOT 241
20.13.2 PRODUCT PORTFOLIO 241
20.13.3 RECENT DEVELOPMENT 241
20.14 ELABSCIENCE BIOTECHNOLOGY INC. 242
20.14.1 COMPANY SNAPSHOT 242
20.14.2 PRODUCT PORTFOLIO 242
20.14.3 RECENT DEVELOPMENT 242
20.15 EPIGENOMICS AG 243
20.15.1 COMPANY SNAPSHOT 243
20.15.2 REVENUE ANALYSIS 243
20.15.3 PRODUCT PORTFOLIO 244
20.15.4 RECENT DEVELOPMENT 244
20.16 FUJIFILM CORPORATION 245
20.16.1 COMPANY SNAPSHOT 245
20.16.2 REVENUE ANALYSIS 245
20.16.3 PRODUCT PORTFOLIO 246
20.16.4 RECENT DEVELOPMENT 246
20.17 FUJIREBIO 247
20.17.1 COMPANY SNAPSHOT 247
20.17.2 PRODUCT PORTFOLIO 247
20.17.3 RECENT DEVELOPMENTS 247
20.18 HIPRO BIOTECHNOLOGY CO., LTD. 248
20.18.1 COMPANY SNAPSHOT 248
20.18.2 PRODUCT PORTFOLIO 248
20.18.3 RECENT DEVELOPMENT 248
20.19 ILLUMINA, INC. 249
20.19.1 COMPANY SNAPSHOT 249
20.19.2 REVENUE ANALYSIS 249
20.19.3 PRODUCT PORTFOLIO 250
20.19.4 RECENT DEVELOPMENTS 251
20.20 MOLGEN 252
20.20.1 COMPANY SNAPSHOT 252
20.20.2 PRODUCT PORTFOLIO 252
20.20.3 RECENT DEVELOPMENT 252
20.21 QIAGEN 253
20.21.1 COMPANY SNAPSHOT 253
20.21.2 REVENUE ANALYSIS 253
20.21.3 PRODUCT PORTFOLIO 254
20.21.4 RECENT DEVELOPMENT 254

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.